Charles Zhu
Stock Analyst at Guggenheim
(4.40)
# 1,205
Out of 4,479 analysts
16
Total ratings
55%
Success rate
23.32%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $16 → $14 | $9.00 | +55.56% | 1 | May 24, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $4.30 | +179.07% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $54.45 | -11.85% | 3 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $75.51 | -25.84% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $2.09 | +952.63% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $8.94 | +190.83% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $35.92 | -10.91% | 2 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $8.61 | +62.60% | 1 | May 5, 2022 |
Tango Therapeutics
May 24, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $9.00
Upside: +55.56%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $4.30
Upside: +179.07%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $54.45
Upside: -11.85%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $75.51
Upside: -25.84%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $2.09
Upside: +952.63%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $8.94
Upside: +190.83%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $35.92
Upside: -10.91%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $8.61
Upside: +62.60%